Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Arming "old guards" with "new dual-targeting weapons".

Lawrence G Lum1, Jogender Tushir-Singh2

  • 1Stem Cell Transplantation Program and Cellular Therapy Program, Division of Oncology/Hematology, Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA, USA.

Cancer Cell
|May 11, 2021
PubMed
Summary

Researchers challenge the idea that tumor suppressors are untargetable in cancer. A new study introduces a novel antibody strategy to eliminate tumors expressing specific neoantigens, offering new hope for cancer therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An evolutionary T119R substitution in the macaque T-cell immunoreceptor TIGIT enables proteolytic shedding and reveals clinical antibody vulnerabilities.

The Journal of biological chemistry·2025
Same author

LAG3+ CD8+ T cell subset drives HR+/HER2- breast cancer reduction in bispecific antibody armed activated T cell therapy.

Journal of immunology (Baltimore, Md. : 1950)·2025
Same author

LAG3+ CD8+ T cell Subset Drives HR+/HER2- Breast Cancer Reduction in Bispecific Antibody Armed Activated T Cell Therapy.

bioRxiv : the preprint server for biology·2025
Same author

Targeting microRNA-dependent control of X chromosome inactivation improves the Rett Syndrome phenotype.

Nature communications·2025
Same author

Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapy.

Nature communications·2025
Same author

Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma.

Journal for immunotherapy of cancer·2025

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • The concept of tumor suppressors being untargetable in cancer therapy has been a long-standing paradigm.
  • Targeting tumor suppressor proteins presents significant challenges in developing effective cancer treatments.

Purpose of the Study:

  • To challenge the paradigm of untargetable tumor suppressors.
  • To characterize a novel p53 mutant peptide-selective TCR-mimic antibody.
  • To develop a co-targeting T cell-activating bispecific antibody for tumor elimination.

Main Methods:

  • Development and characterization of a T cell receptor (TCR)-mimic antibody targeting a specific p53 mutant peptide.
  • Design of a bispecific antibody for co-targeting tumor neoantigens and T cells.

Related Experiment Videos

  • In vitro and in vivo studies to assess the efficacy of the antibody combination in eliminating neoantigen-expressing tumors.

    • Main Results:

    • The study successfully describes and characterizes a p53 mutant peptide-selective TCR-mimic antibody.
    • A co-targeting T cell-activating bispecific antibody was developed and shown to be effective.
    • The antibody strategy demonstrated the ability to eliminate neoantigen-expressing tumors, challenging the untargetable tumor suppressor paradigm.

    Conclusions:

    • The findings challenge the long-held belief that tumor suppressors are untargetable in cancer therapy.
    • The developed TCR-mimic and bispecific antibodies offer a promising new therapeutic strategy for cancers expressing specific neoantigens.
    • This approach provides a potential avenue for targeting previously undruggable cancer targets.